Compare FTW & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTW | LCTX |
|---|---|---|
| Founded | 2017 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.6M | 251.4M |
| IPO Year | 2026 | 1996 |
| Metric | FTW | LCTX |
|---|---|---|
| Price | $10.21 | $1.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $15.00 | $5.50 |
| AVG Volume (30 Days) | 51.8K | ★ 1.4M |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | ★ 13.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | $32.44 | $4.38 |
| Revenue Next Year | $3.93 | $10.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $9.46 | $0.88 |
| 52 Week High | $17.20 | $1.99 |
| Indicator | FTW | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.01 | 58.80 |
| Support Level | $9.99 | $1.02 |
| Resistance Level | $10.54 | $1.18 |
| Average True Range (ATR) | 0.20 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 44.50 | 96.22 |
Presidio Production Co is an independent oil and natural gas company engaged in oil and gas exploration and production, with operations concentrated across the Western Anadarko Basin of Texas, Oklahoma, and Kansas. It oeprates in one reportable segment, which is engaged in the acquisition, development, exploration, and production of oil and natural gas properties. It derives its revenue from customers through the sale of oil, natural gas, and NGLs as well as other immaterial service contracts in United States.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.